Pedro Vilela/Getty Images
We have a covid-19 vaccine that works. But can we keep it cold enough to get it to enough people? Among Pfizer and BioNTech’s long list of risks and uncertainties for its BNT162b2 vaccine, which this week was reported to be 90 per cent effective, is the challenge of its “ultra-low temperature formulation”, and how to store and distribute it along the so-called “cold chain”.
Between manufacture and doses …
source: newscientist.com